Back to Search
Start Over
National Shortages of Generic Sterile Injectable Drugs
- Source :
- JAMA. 317:1415
- Publication Year :
- 2017
- Publisher :
- American Medical Association (AMA), 2017.
-
Abstract
- For decades, US physicians could assume that any approved drug they prescribed would be available. However, since the turn of the 21st century, the United States now regularly experiences national drug shortages, defined by the US Food and Drug Administration (FDA) as situations in which the “total supply of all clinically interchangeable versions of an FDA-regulated drug is inadequate to meet the current or projected demand at the patient level.”1 The most challenging year so far was 2011, with 251 drug shortages, of which 73% were generic sterile injectable drugs, including many medications required to treat sepsis, cancer, and other life-threatening conditions.2 One of these drugs was norepinephrine, recommended in international guidelines as the primary vasopressor for treatment of septic shock.3 In this issue of JAMA, Vail and colleagues4 report a study examining whether the 2011 norepinephrine shortage was associated with changes in care and outcome.
- Subjects :
- Drug
medicine.medical_specialty
Drug Industry
business.industry
media_common.quotation_subject
Economic shortage
General Medicine
030204 cardiovascular system & hematology
Approved drug
Surgery
Norepinephrine (medication)
Food and drug administration
Norepinephrine
03 medical and health sciences
0302 clinical medicine
Potential harm
Infertility
Drugs, Generic
Humans
Medicine
030212 general & internal medicine
business
Intensive care medicine
media_common
medicine.drug
Subjects
Details
- ISSN :
- 00987484
- Volume :
- 317
- Database :
- OpenAIRE
- Journal :
- JAMA
- Accession number :
- edsair.doi.dedup.....a3e372b88f9e5fea4f83380e68c07332